Beyang Therapeutics Raises Nearly RMB 200 Million as AI-Designed Drugs Approach Clinical Validation

The value of artificial intelligence in drug development must ultimately be tested in human trials. Chinese startup Beyang Therapeutics has completed a Series A financing of nearly RMB 200 million, or approximately US$28 million to US$30 million. It is preparing to advance two small-molecule drugs designed and optimized with the assistance of its computational platform, giving the market an opportunity to assess whether this approach can bridge the gap between early-stage research and clinical development.

According to VCBeat, the financing was jointly led by Legend Capital and the Shanghai Biomedical Innovation and Transformation Fund. Participants included China Medical System Holdings, Fenglei Capital, Shanghai Sci-Tech Innovation Fund, and IFSC, while existing shareholders including Oriza Seed and Baidu Ventures continued to invest. Investment information disclosed earlier differed slightly in how some institutions’ names and roles were described, but all reports referred to the same Series A financing. The proceeds will be used to upgrade the ExCEED platform, advance clinical and preclinical pipelines, and expand overseas research and development and business teams.

ExCEED is not simply a model that generates molecular images. It integrates molecular generation and structural optimization, experimental evaluation, and DMPK simulation into a single workflow. DMPK covers a drug’s absorption, distribution, metabolism, and excretion, with the aim of eliminating candidates with insufficient exposure, metabolic instability, or other poor drug-like properties early in the design process. However, the company has not disclosed platform datasets, prediction accuracy, or success rates relative to conventional drug development processes that would enable independent comparison. At this stage, evidence of the platform’s value still comes primarily from pipeline progress.

The more advanced candidate, BT01001, is a small-molecule ophthalmic solution being developed for indications including diabetic retinopathy. Public trial information shows that its Phase 1 study is recruiting healthy adults and uses a randomized, double-blind, placebo-controlled, dose-escalation design to evaluate the safety, tolerability, and pharmacokinetics of concentrations of 0.5%, 1.0%, and 1.5%. If administration through eye drops can deliver a sufficient amount of the drug to the back of the eye, it could theoretically reduce the burden of intravitreal injections. However, this trial is not an efficacy study in patients and cannot yet demonstrate that the drug can improve retinopathy.

Another candidate, BT01002, also known as BY002, is described as a second-generation menin inhibitor targeting acute leukemia and remains at the stage of studies supporting an investigational new drug application. Menin inhibition has become a clinical development pathway for certain molecular subtypes of leukemia. A “second-generation” candidate must therefore demonstrate differentiation beyond activity through selectivity, coverage of resistance mutations, pharmacokinetics, or safety. The data currently disclosed by Beyang remain insufficient for such comparisons.

This financing therefore buys not an answer about the AI drug-development model, but two opportunities for more rigorous validation. BT01001 must first establish safety in humans and ocular exposure before entering patient trials. BY002 must complete preclinical safety assessments and obtain authorization for clinical trials. If both can translate computational predictions into reproducible clinical results, ExCEED may then progress from a research and development tool into a platform with value for external partnerships.